

## AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-14. **(Canceled)**

15. **(Currently Amended)** A method for treating arthritis comprising administering by injection to a subject an anti-TNF $\alpha$  antibody, or an antigen-binding portion thereof, in a low dose of 0.01 – 0.1 mg/kg at a frequency of not more than once per week, such that the arthritis is treated.

16. **(Original)** The method of claim 15, wherein the arthritis is rheumatoid arthritis.

17. **(Previously presented)** The method of any one of claims 15 or 16, wherein arthritis is treated by alleviating symptoms selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity.

18-20. **(Canceled)**

21. **(Currently Amended)** A low dose method for alleviating symptoms associated with arthritis comprising administering by injection to a subject an anti-TNF $\alpha$  antibody, or an antigen-binding portion thereof, in a low dose of 0.01 – 0.1 mg/kg at a frequency of not more than once per week, such that the symptoms are alleviated.

22. **(Previously presented)** The method of claim 21, wherein the arthritis is rheumatoid arthritis.

23. **(Previously presented)** The method of any one of claims 21 or 22, wherein the symptoms are selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity.

24. **(Original)** The method of claim 23, wherein the symptoms are further selected from the group consisting of joint distortion, swelling, joint deformation, ankylosis on flexion, and severely impaired movement.

25-30. **(Canceled)**

31. **(Previously presented)** The method of any one of claims 15 or 21, wherein the anti-TNF $\alpha$  antibody, or an antigen-binding portion thereof, is administered with an additional therapeutic agent.

32-33. **(Canceled)**

34. **(Previously presented)** The method of any one of claims 15 or 16, wherein the anti-TNF $\alpha$  antibody, or an antigen-binding portion thereof, is either infliximab or D2E7.

35. **(Previously presented)** The method of any one of claims 21 or 22, wherein the anti-TNF $\alpha$  antibody, or an antigen-binding portion thereof, is either infliximab or D2E7.

36-39. **(Canceled)**

40. **(Previously presented)** The method of any one of claims 15, 16, 21 or 22, wherein the anti-TNF $\alpha$  antibody, or an antigen-binding portion thereof, is human.

41. **(Previously presented)** The method of claim 40, wherein the anti-TNF $\alpha$  antibody, or antigen-binding portion thereof, dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8}$  M or less and a  $K_{off}$  rate constant of  $1 \times 10^{-3} \text{ s}^{-1}$  or less, both determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a standard *in vitro* L929 assay with an  $IC_{50}$  of  $1 \times 10^{-7}$  M or less.

42. **(Currently Amended)** A low dose method for treating rheumatoid arthritis comprising administering by injection to a subject a low dose of 0.01 – 0.1 mg/kg of a human TNF $\alpha$  antibody, or an antigen-binding portion thereof, at a frequency of not more than once per week such that the rheumatoid arthritis is treated.

43. **(Previously presented)** The method of claim 42, wherein rheumatoid arthritis is treated by alleviating symptoms selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity, are treated.

44. **(Previously presented)** The method of claim 42, wherein the human anti-TNF $\alpha$  antibody, or antigen-binding portion thereof, dissociates from human TNF $\alpha$  with a  $K_D$  of  $1 \times 10^{-8}$  M or less and a  $K_{off}$  rate constant of  $1 \times 10^{-3}$  s $^{-1}$  or less, both determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a standard *in vitro* L929 assay with an IC $_{50}$  of  $1 \times 10^{-7}$  M or less.

45. **(Previously presented)** The method of claim 44, wherein the anti-TNF $\alpha$  antibody, or antigen-binding portion thereof, is D2E7.

46-47. **(Canceled)**

48. **(Currently Amended)** A low dose method of improving symptoms in the joints of a subject having arthritis comprising administering by injection to the subject a low dose of 0.01-0.1 mg/kg of a human anti-TNF $\alpha$  antibody, or antigen-binding portion thereof, at a frequency of not more than once per week such that at least one symptom selected from the group consisting of inflammation, cartilage erosion, bone erosion, and vascularity is improved.

49. **(Previously presented)** The method of claim 48, wherein the human anti-TNF $\alpha$  antibody, or antigen-binding portion thereof, is D2E7.

50-51. **(Canceled)**

52. **(Currently Amended)** A low dose method for treating arthritis comprising administering to a subject a human anti-TNF $\alpha$  antibody, or an antigen-binding portion thereof, in a low dose of 0.01 – 0.1 mg/kg at a frequency of not more than once per week, such that the arthritis is treated.

53. **(Currently Amended)** A low dose method for alleviating symptoms associated with arthritis comprising administering to a subject an effective amount of a human anti-TNF $\alpha$  antibody, or an antigen-binding portion thereof, in a low dose of 0.01 – 0.1 mg/kg at a frequency of not more than once per week, such that the symptoms are alleviated.